

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

F1_M3

C Number: C20523
Lock Date: 02/24/2009
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.3.1
PWG Approval Date: NONE

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF METAL WORKING FLUIDS (TRIM VX)

MALE MICE

Organ

Larynx

Lung

Lung: Bronchiole

Nose

Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

FEMALE MICE

Organ

Larynx

Lung

Lung: Bronchiole

Nose

Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

Morphology

Hyperplasia

Inflammation Chronic

Metaplasia

Fibrosis

Infiltration Cellular Histiocyte

Inflammation Chronic

Hyperplasia

Inflammation

Accumulation, Hyaline Droplet

Accumulation, Hyaline Droplet

Morphology

Hyperplasia

Inflammation Chronic

Metaplasia

Fibrosis

Infiltration Cellular Histiocyte

Inflammation Chronic

Hyperplasia

Inflammation

Accumulation, Hyaline Droplet

Accumulation, Hyaline Droplet

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Adrenal Cortex						
Accessory Adrenal Cortical Nodule						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	10%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	95 (T)	---	---	---	---	95 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.760
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.760
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.760
COCH-ARM / FISHERS	P=0.650	(e)	(e)	(e)	(e)	P=0.763N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=1.000

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Adrenal Cortex						
Vacuolization Cytoplasmic						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Adrenal Cortex: Subcapsular						
Accessory Adrenal Cortical Nodule						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Adrenal Cortex: Subcapsular Hyperplasia						
LESION RATES						
OVERALL (a)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	2/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	20%	0%	0%	0%	0%	10%
TERMINAL (d)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	95 (T)	---	---	---	---	95 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.381N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.274N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Kidney Cyst						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Kidney						
Inflammation Chronic						
LESION RATES						
OVERALL (a)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	2/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	20%	0%	0%	0%	0%	10%
TERMINAL (d)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	95 (T)	---	---	---	---	95 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.381N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.274N

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Kidney						
Nephropathy						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	0%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	95 (T)	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.309N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Larynx Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	2/10 (20%)	9/10 (90%)	8/10 (80%)	9/10 (90%)
POLY-3 RATE (b)	0/10.00	0/10.00	2/10.00	9/10.00	8/10.00	9/10.00
POLY-3 PERCENT (g)	0%	0%	20%	90%	80%	90%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	2/10 (20%)	9/10 (90%)	8/10 (80%)	9/10 (90%)
FIRST INCIDENCE	---	---	95 (T)	95 (T)	95 (T)	95 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	P=0.227	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.227	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.227	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.237	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.066	P<0.001**	P<0.001**	P<0.001**

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Larynx						
Inflammation Chronic						
LESION RATES						
OVERALL (a)	0/10 (0%)	4/10 (40%)	0/10 (0%)	3/10 (30%)	1/10 (10%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	4/10.00	0/10.00	3/10.00	1/10.00	0/10.00
POLY-3 PERCENT (g)	0%	40%	0%	30%	10%	0%
TERMINAL (d)	0/10 (0%)	4/10 (40%)	0/10 (0%)	3/10 (30%)	1/10 (10%)	0/10 (0%)
FIRST INCIDENCE	---	95 (T)	---	95 (T)	95 (T)	---
STATISTICAL TESTS						
POLY 3	P=0.160N	P=0.033*	(e)	P=0.095	P=0.500	(e)
POLY 1.5	P=0.160N	P=0.033*	(e)	P=0.095	P=0.500	(e)
POLY 6	P=0.160N	P=0.033*	(e)	P=0.095	P=0.500	(e)
COCH-ARM / FISHERS	P=0.178N	P=0.043*	(e)	P=0.105	P=0.500	(e)
MAX-ISO-POLY-3	P=0.078N	P=0.007**	(e)	P=0.025*	P=0.158	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Larynx						
Metaplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	95 (T)	95 (T)	95 (T)	95 (T)	95 (T)
STATISTICAL TESTS						
POLY 3	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Lung Fibrosis						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	1/10 (10%)	8/10 (80%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	1/10.00	8/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	10%	80%	100%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	1/10 (10%)	8/10 (80%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	---	95 (T)	95 (T)	95 (T)	95 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.158	P<0.001**	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Lung						
Infiltration Cellular Histiocyte						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	2/10 (20%)	9/10 (90%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	2/10.00	9/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	20%	90%	100%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	2/10 (20%)	9/10 (90%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	---	95 (T)	95 (T)	95 (T)	95 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	P=0.227	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.227	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.227	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.237	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.066	P<0.001**	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Lung						
Inflammation Chronic						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	4/10 (40%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	4/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	40%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	4/10 (40%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	---	95 (T)	95 (T)	95 (T)	95 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.043*	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.007**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Lung: Bronchiole Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	9/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	90%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	---	95 (T)	95 (T)	95 (T)	95 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P<0.001**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Nose Inflammation						
LESION RATES						
OVERALL (a)	0/10 (0%)	7/10 (70%)	8/10 (80%)	8/10 (80%)	8/10 (80%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	7/10.00	8/10.00	8/10.00	8/10.00	10/10.00
POLY-3 PERCENT (g)	0%	70%	80%	80%	80%	100%
TERMINAL (d)	0/10 (0%)	7/10 (70%)	8/10 (80%)	8/10 (80%)	8/10 (80%)	10/10 (100%)
FIRST INCIDENCE	---	95 (T)	95 (T)	95 (T)	95 (T)	95 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Nose: Olfactory Epithelium Accumulation, Hyaline Droplet						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	95 (T)	95 (T)	95 (T)	95 (T)	95 (T)
STATISTICAL TESTS						
POLY 3	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Nose: Respiratory Epithelium Accumulation, Hyaline Droplet						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	95 (T)	95 (T)	95 (T)	95 (T)	95 (T)
STATISTICAL TESTS						
POLY 3	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Nose: Respiratory Epithelium Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Testes: Germinal Epithelium Degeneration						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	0%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	95 (T)	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.309N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158N

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Adrenal Cortex						
Accessory Adrenal Cortical Nodule						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/1.00	0/1.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Adrenal Cortex						
Vacuolization Cytoplasmic						
LESION RATES						
OVERALL (a)	6/10 (60%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	4/10 (40%)
POLY-3 RATE (b)	6/10.00	0/0.00	0/1.00	0/1.00	0/0.00	4/10.00
POLY-3 PERCENT (g)	60%	0%	0%	0%	0%	40%
TERMINAL (d)	6/10 (60%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	4/10 (40%)
FIRST INCIDENCE	96 (T)	---	---	---	---	96 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	P=0.463N	P=0.463N	(e)	P=0.333N
POLY 1.5	(e)	(e)	P=0.463N	P=0.463N	(e)	P=0.333N
POLY 6	(e)	(e)	P=0.463N	P=0.463N	(e)	P=0.333N
COCH-ARM / FISHERS	P=0.345N	(e)	P=0.455N	P=0.455N	(e)	P=0.328N
MAX-ISO-POLY-3	(e)	(e)	P=0.205N	P=0.205N	(e)	P=0.193N

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Adrenal Cortex: Subcapsular Accessory Adrenal Cortical Nodule						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/1.00	0/1.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	10%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	96 (T)	---	---	---	---	96 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	P=0.913N	P=0.913N	(e)	P=0.760
POLY 1.5	(e)	(e)	P=0.913N	P=0.913N	(e)	P=0.760
POLY 6	(e)	(e)	P=0.913N	P=0.913N	(e)	P=0.760
COCH-ARM / FISHERS	P=0.620	(e)	P=0.909N	P=0.909N	(e)	P=0.763N
MAX-ISO-POLY-3	(e)	(e)	P=0.409N	P=0.409N	(e)	P=1.000

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Adrenal Cortex: Subcapsular Hyperplasia						
LESION RATES						
OVERALL (a)	5/10 (50%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	5/10 (50%)
POLY-3 RATE (b)	5/10.00	0/0.00	0/1.00	0/1.00	0/0.00	5/10.00
POLY-3 PERCENT (g)	50%	0%	0%	0%	0%	50%
TERMINAL (d)	5/10 (50%)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	5/10 (50%)
FIRST INCIDENCE	96 (T)	---	---	---	---	96 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	P=0.536N	P=0.536N	(e)	P=0.664
POLY 1.5	(e)	(e)	P=0.536N	P=0.536N	(e)	P=0.664
POLY 6	(e)	(e)	P=0.536N	P=0.536N	(e)	P=0.664
COCH-ARM / FISHERS	P=0.489	(e)	P=0.545N	P=0.545N	(e)	P=0.672N
MAX-ISO-POLY-3	(e)	(e)	P=0.251N	P=0.251N	(e)	P=1.000

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Kidney Cyst						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	0%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	96 (T)	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.309N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158N

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Kidney						
Inflammation Chronic						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Kidney						
Nephropathy						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	10%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	96 (T)	---	---	---	---	96 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.760
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.760
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.760
COCH-ARM / FISHERS	P=0.650	(e)	(e)	(e)	(e)	P=0.763N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=1.000

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Larynx Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	1/10 (10%)	7/10 (70%)	7/10 (70%)	8/10 (80%)
POLY-3 RATE (b)	0/10.00	0/10.00	1/10.00	7/10.00	7/10.00	8/10.00
POLY-3 PERCENT (g)	0%	0%	10%	70%	70%	80%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	1/10 (10%)	7/10 (70%)	7/10 (70%)	8/10 (80%)
FIRST INCIDENCE	---	---	96 (T)	96 (T)	96 (T)	96 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.500	P=0.002**	P=0.002**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.158	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Larynx						
Inflammation Chronic						
LESION RATES						
OVERALL (a)	0/10 (0%)	4/10 (40%)	5/10 (50%)	8/10 (80%)	9/10 (90%)	5/10 (50%)
POLY-3 RATE (b)	0/10.00	4/10.00	5/10.00	8/10.00	9/10.00	5/10.00
POLY-3 PERCENT (g)	0%	40%	50%	80%	90%	50%
TERMINAL (d)	0/10 (0%)	4/10 (40%)	5/10 (50%)	8/10 (80%)	9/10 (90%)	5/10 (50%)
FIRST INCIDENCE	---	96 (T)	96 (T)	96 (T)	96 (T)	96 (T)
STATISTICAL TESTS						
POLY 3	P=0.037*	P=0.033*	P=0.008**	P<0.001**	P<0.001**	P=0.008**
POLY 1.5	P=0.037*	P=0.033*	P=0.008**	P<0.001**	P<0.001**	P=0.008**
POLY 6	P=0.037*	P=0.033*	P=0.008**	P<0.001**	P<0.001**	P=0.008**
COCH-ARM / FISHERS	P=0.063	P=0.043*	P=0.016*	P<0.001**	P<0.001**	P=0.016*
MAX-ISO-POLY-3	P<0.001**	P=0.007**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Larynx						
Metaplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	96 (T)	96 (T)	96 (T)	96 (T)	96 (T)
STATISTICAL TESTS						
POLY 3	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Lung Fibrosis						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	0%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	---	---	96 (T)	96 (T)	96 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	(e)	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Lung						
Infiltration Cellular Histiocyte						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	1/10 (10%)	5/10 (50%)	9/10 (90%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	1/10.00	5/10.00	9/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	10%	50%	90%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	1/10 (10%)	5/10 (50%)	9/10 (90%)	10/10 (100%)
FIRST INCIDENCE	---	---	96 (T)	96 (T)	96 (T)	96 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	P=0.500	P=0.008**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.500	P=0.008**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.500	P=0.008**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.500	P=0.016*	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.158	P<0.001**	P<0.001**	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Lung						
Inflammation Chronic						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/10 (0%)	2/10 (20%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	1/10.00	0/10.00	2/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	10%	0%	20%	100%	100%	100%
TERMINAL (d)	1/10 (10%)	0/10 (0%)	2/10 (20%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	96 (T)	---	96 (T)	96 (T)	96 (T)	96 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P=0.500N	P=0.500	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.500N	P=0.500	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.500N	P=0.500	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.500N	P=0.500	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.158N	P=0.274	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Lung: Bronchiole Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	4/10 (40%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	4/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	40%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	4/10 (40%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	---	96 (T)	96 (T)	96 (T)	96 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.043*	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.007**	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Nose Inflammation						
LESION RATES						
OVERALL (a)	0/10 (0%)	1/10 (10%)	6/10 (60%)	5/10 (50%)	10/10 (100%)	7/10 (70%)
POLY-3 RATE (b)	0/10.00	1/10.00	6/10.00	5/10.00	10/10.00	7/10.00
POLY-3 PERCENT (g)	0%	10%	60%	50%	100%	70%
TERMINAL (d)	0/10 (0%)	1/10 (10%)	6/10 (60%)	5/10 (50%)	10/10 (100%)	7/10 (70%)
FIRST INCIDENCE	---	96 (T)	96 (T)	96 (T)	96 (T)	96 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P=0.500	P<0.001**	P=0.008**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.500	P<0.001**	P=0.008**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.500	P<0.001**	P=0.008**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.500	P=0.005**	P=0.016*	P<0.001**	P=0.002**
MAX-ISO-POLY-3	P<0.001**	P=0.158	P<0.001**	P<0.001**	(e)	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Nose: Olfactory Epithelium Accumulation, Hyaline Droplet						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	96 (T)	96 (T)	96 (T)	96 (T)	96 (T)
STATISTICAL TESTS						
POLY 3	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Nose: Respiratory Epithelium Accumulation, Hyaline Droplet						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	96 (T)	96 (T)	96 (T)	96 (T)	96 (T)
STATISTICAL TESTS						
POLY 3	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20523 - 02

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Metal working fluids (Trim VX)

CAS Number: TRIMVX

Date Report Requested: 03/24/2011

Time Report Requested: 15:32:43

First Dose M/F: 07/14/08 / 07/14/08

Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Nose: Respiratory Epithelium Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	1/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	10%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	96 (T)	---
STATISTICAL TESTS						
POLY 3	P=0.605	(e)	(e)	(e)	P=0.500	(e)
POLY 1.5	P=0.605	(e)	(e)	(e)	P=0.500	(e)
POLY 6	P=0.605	(e)	(e)	(e)	P=0.500	(e)
COCH-ARM / FISHERS	P=0.605	(e)	(e)	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.193	(e)	(e)	(e)	P=0.158	(e)

LEGEND

- (a) Number of tumor-bearing animals/number of animals examined at site.
 - (b) Number of tumor-bearing animals/Poly-3 number
 - (d) Observed incidence at terminal kill.
 - (e) Value of statistic cannot be computed.
 - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
 - (g) Poly-3 adjusted lifetime tumor incidence.
 - (n) No statistics are calculated if all dose groups have fewer than two tumors.
 - (I) Interim sacrifice
 - (T) Terminal sacrifice
 - # Tumor rates based on numbers of animals necropsied.
 - * To the right of any statistical result, indicates significance at ($P \leq 0.05$).
 - ** To the right of any statistical result, indicates significance at ($P \leq 0.01$).
 - N Indicates a negative trend for all tests
- The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***